Gleneagles Hospital Hong Kong’s Peritoneal Malignancy Treatment Centre has introduced new intraperitoneal chemotherapy procedures, including Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Pressurised Intraperitoneal Aerosol Chemotherapy (PIPAC), to provide more effective treatment to patients with peritoneal cancer.
Dr Kenneth Tsang, Chief Executive Officer of Gleneagles Hospital Hong Kong, said, “In addition to our advanced radiotherapy facilities, we have also launched a centre dedicated to serving patients with peritoneal metastasis. Our experienced multidisciplinary medical team provides patients with comprehensive diagnostic services and personalised treatments.” The Centre is the first of its kind in Hong Kong catering to patients with peritoneal metastasis. Medical studies have found HIPEC to effectively improve the survival rate of patients with ovarian cancer, gastric cancer or colorectal cancer. The innovative PIPAC treatment is also known to relieve symptoms of peritoneal metastasis and reduce the side effects of chemotherapy, which helps improve the patient’s quality of life.
Related Stories
IHH Healthcare Deepens Commitment to Reduce Cancer Burden in Malaysia
Learn how our third memorandum of understanding with Ministry of Health Malaysia is expanding access to life-saving, advanced cancer care at 8 of our hospitals.
IHH Healthcare Bags Five Wins at the 15th Asian Excellence Awards
Celebrating our leadership, sustainability, and investor relations excellence on the regional stage.
Fortis CEO Shares Vision for a Healthier India on NDTV
Here is a look at how Fortis is contributing to India’s healthcare transformation.
IHH Singapore Hits New Digital and Imaging Milestones
Across Singapore, IHH Healthcare is transforming care delivery through data, technology and frontline innovation.
Parkway Radiology Deploys Annalise.ai Chest X-ray AI Solution
Parkway Radiology has implemented the Annalise.ai Enterprise CXR solution across all its radiology clinics and hospital departments in Singapore. This represents the first network-wide deployment of the chest X-ray AI technology in the country.
Fortis Enhances Diagnostic and Paediatric Care at S L Raheja Hospital, Mumbai
S L Raheja Hospital, a Fortis Associate, has significantly expanded its diagnostic and paediatric capabilities with the launch of AI-enabled Digital Positron Emission Tomography–Computed Tomography (PET-CT), 3 Tesla Magnetic Resonance Imaging (MRI), and upgraded Neonatal Intensive Care Unit (NICU) and Paediatric Intensive Care Unit (PICU) services.
